Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

07 déc. 2017 18h00 HE | Source: MediciNova, Inc.

MediciNova Announces Positive Top-Line Results from the Clinical Trial of MN-166 (ibudilast) in ALS

LA JOLLA, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
10 nov. 2017 01h30 HE | Source: MediciNova, Inc.

MediciNova Appoints Hideki Nagao to its Board of Directors

LA JOLLA, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
09 nov. 2017 18h00 HE | Source: MediciNova, Inc.

MediciNova Announces Collaboration with the U.S. Department of Veterans Affairs and Oregon Health & Science University to Evaluate MN-166 (ibudilast) in Methamphetamine Use Disorder

LA JOLLA, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
01 nov. 2017 19h00 HE | Source: MediciNova, Inc.

MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 28th International Symposium on ALS/MND in Boston, MA, USA

LA JOLLA, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
30 oct. 2017 06h00 HE | Source: MediciNova, Inc.

MediciNova Announces the Presentation of Additional Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS: Achieved a Statistically Significant 48% Reduction in Whole Brain Atrophy with a Favorable Safety and Tolerability Profile

LA JOLLA, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
26 oct. 2017 06h00 HE | Source: MediciNova, Inc.

MediciNova Announces Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS: Achieved Both Primary Endpoints including a Significant Reduction in Whole Brain Atrophy and Safety and Tolerability

LA JOLLA, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
19 sept. 2017 06h00 HE | Source: MediciNova, Inc.

MediciNova Announces the Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence

LA JOLLA, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
18 sept. 2017 19h00 HE | Source: MediciNova, Inc.

MediciNova to Present at the Ladenburg Thalmann 2017 Healthcare Conference in New York

LA JOLLA, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
30 août 2017 06h00 HE | Source: MediciNova, Inc.

MediciNova Announces the Abstract from the MN-166 (ibudilast) SPRINT-MS Phase 2b Study in Progressive MS - including Top Line Data - was Selected as a Platform Presentation for Late-Breaking Presentation at the 7th Joint ECTRIMS - ACTRIMS Meeting on October 28, 2017 in Paris, France

LA JOLLA, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
05 juin 2017 16h00 HE | Source: MediciNova, Inc.

MediciNova Announces Positive Results from a Glioblastoma Animal Model Study Presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois

LA JOLLA, Calif., June 05, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...

Page précédente

Page suivante